Search Results - "Saif, Saiful Islam"

Computational screening of 645 antiviral peptides against the receptor-binding domain of the spike protein in SARS-CoV-2 by Sakib, Md Minhas Hossain, Nishat, Aktiya Anjum, Islam, Mohammad Tarequl, Raihan Uddin, Mohammad Abu, Iqbal, Md Shahriar, Bin Hossen, Farhan Fuad, Ahmed, Mohammad Imran, Bashir, Md Samiul, Hossain, Takbir, Tohura, Umma Sumia, Saif, Saiful Islam, Jui, Nabilah Rahman, Alam, Mosharaf, Islam, Md Aminul, Hasan, Md Mehadi, Sufian, Md Abu, Ali, Md Ackas, Islam, Rajib, Hossain, Mohammed Akhter, Halim, Mohammad A.

“…The receptor-binding domain (RBD) of SARS-CoV-2 spike (S) protein plays a vital role in binding and internalization through the alpha-helix (AH) of human…”
Get full text

Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Daratumumab-Naïve Relapsed Multiple Myeloma: Multicenter Real-World Experience by Mansour, Razan, Davis, James A, Minchak, Megan, Atallah, Rawan, Saif, Md Saiful Islam, Logan, Emerson, Tabak, Carine, Rashid, Aliya, Dima, Danai, Ahmed, Nausheen, Abdallah, Al-Ola, Hashmi, Hamza

“…Background: Daratumumab is an anti-CD38 monoclonal antibody approved in combination with pomalidomide/dexamethasone (DPd) and carfilzomib/dexamethasone (DKd)…”
Get full text

Trends in Access to Cellular Therapies in Multiple Myeloma (TACTUM): Perspectives of Treating Versus Referring Physicians by Atallah, Rawan, Saif, Md Saiful Islam, Dima, Danai, Shrestha, Anuj, Anwer, Faiz, Mushtaq, Muhammad Umair, Lutfi, Forat, Shune, Leyla, Hashmi, Hamza, Ganguly, Siddhartha, McGuirk, Joseph P, Atrash, Shebli, Abdallah, Al-Ola, Banerjee, Rahul, Ahmed, Nausheen

“…Introduction: Approved BCMA-directed cellular therapies (BDCT) for multiple myeloma (MM) include chimeric antigen receptor T cell therapies (CART):…”
Get full text

Balancing Monitoring and Access: Optimal Duration of Monitoring for CD19 and BCMA CART Recipients for Lymphoma and Myeloma by Wesson, William, Rashid, Aliya, Saif, Md Saiful Islam, Logan, Emerson, Tabak, Carine, McGann, Mary, Davis, James A, Hazlett, Liz, Lutfi, Forat, Mushtaq, Muhammad Umair, Abdallah, Al-Ola, Hoffmann, Marc S., Hashmi, Hamza, McGuirk, Joseph P, Hamadani, Mehdi, Ahmed, Nausheen

“…Background: Due to the risks of cytokine release syndrome (CRS) and immune effector cell-associated neurologic syndromes (ICANS), a four-week monitoring period…”
Get full text

TACTUM: Trends in Access to Cellular Therapies in Multiple Myeloma, Perspectives of Treating Versus Referring Physicians by Atallah, Rawan, Ahmed, Nausheen, Ayoobkhan, Fathima, Saif, Md Saiful Islam, Logan, Emerson, Shrestha, Anuj, Anwer, Faiz, Mahmoudjafari, Zahra, Mushtaq, Muhammed Umair, Hashmi, Hamza, Ganguly, Siddhartha, McGuirk, Joseph, Shebli, Atrash, Abdallah, Al-Ola, Banerjee, Rahul, Alkharabsheh, Omar

“…•Barriers perceived by treating/referring oncologists TO/RO for CART and TCE differ.•Financial burden was the top barrier to access identified by RO for both…”
Get full text

Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma by Wesson, William, Dima, Danai, Suleman, Nahid, Saif, Md Saiful Islam, Tabak, Carine, Logan, Emerson, Davis, James A., McGann, Mary, Furqan, Fateeha, Mohan, Meera, Rashid, Aliya, Abdallah, Al–Ola, Ullah, Fauzia, Shune, Leyla, Mushtaq, Muhammad Umair, Raza, Shahzad, McGuirk, Joseph, Hamadani, Mehdi, Anwer, Faiz, Hashmi, Hamza, Ahmed, Nausheen

“…•New-onset CRS/ICANS are rare after two weeks from ide-cel and cilta-cel infusion.•Early NRM (<30 days) is driven by IEC-HS and infection.•Late NRM (30-90…”
Get full text

The TACTUM23 Study: Access to Cellular Therapies in Multiple Myeloma: Perspectives of Treating Versus Referring Physicians in 2023 by Atallah, Rawan, Saif, Md Saiful Islam, Danai, Dima, Shrestha, Anuj, Anwer, Faiz, Mushtaq, Muhammad Umair, Lutfi, Forat, Shune, Leyla, Hashmi, Hamza, Ganguly, Siddhartha MD, McGuirk, Joseph P, Atrash, Shebli, Abdallah, Al-Ola, Banerjee, Rahul, Ahmed, Nausheen, Logan, Emerson

“…Despite promising efficacy and safety profiles of BCMA-directed cellular therapies (BDCT) for multiple myeloma (MM), limited access is a challenge. This survey…”
Get full text

A Multicenter Experience: Duration of Mandatory CRS and Icans Monitoring for Myeloma and Lymphoma CAR-T Recipients by Wesson, William, Dima, Danai, Davis, James, Rashid, Aliya, Furqan, Fateeha, Saif, Md Saiful Islam, Logan, Emerson, McGann, Mary, Tabak, Carine, Hazlett, Liz, Lutfi, Forat, Mushtaq, Muhammad Umair, Hoffmann, Marc, Abdallah, Al-Ola, Anwer, Faiz, Hamadani, Mehdi, McGuirk, Joseph P, Hashmi, Hamza, Ahmed, Nausheen

“…The US Food and Drug Administration implemented a Risk Evaluation and Mitigation Strategy/REMS program for all currently approved BCMA and CD19-directed…”
Get full text

IDENTIFICATION, CORRELATION AND ORIGIN OF THE KEY ANACON-BRUNSWICK MINES ORE HORIZON, BATHURST, NEW BRUNSWICK by SAIF, SAIFUL ISLAM

Get full text